diabetic type 1 and 2 based on Oxford clinical handbook

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Searching Images

type 1 type 2 diabetes comparison classification pathophysiology

Reading File

I now have comprehensive content. Let me compile the full answer from Harrison's 22E (the most authoritative textbook in the library, comparable in scope to the Oxford Handbook).

Note on source: The Oxford Clinical Handbook is not in the medical textbook library. The answer below draws from Harrison's Principles of Internal Medicine, 22nd Edition (2025) - the most comprehensive and authoritative clinical reference available in the library, covering the same core diabetes content as any Oxford handbook chapter.

Diabetes Mellitus: Type 1 and Type 2

(Harrison's Principles of Internal Medicine, 22E, 2025 - pp. 3227-3292)

Classification Overview

Once a diagnosis of DM is made, the type must be classified. Individuals with type 2 DM may present with chronic complications already established at diagnosis (due to long delays in recognition), while those with type 1 DM typically present more acutely.

TYPE 1 DIABETES MELLITUS

Pathophysiology

Type 1 DM results from autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency. Key autoimmune markers include:

Islet cell autoantibodies (ICAs)
Autoantibodies to insulin (IAAs)
Autoantibodies to glutamic acid decarboxylase (GAD65)
Autoantibodies to the tyrosine phosphatases IA-2 and IA-2β
Autoantibodies to zinc transporter 8 (ZnT-8)

Most patients have HLA-DR3 or HLA-DR4 associations; HLA-DQ genes also strongly influence risk. T-lymphocyte-mediated destruction is the primary effector mechanism.

Environmental triggers include coxsackie and enteroviruses, rubella, bovine milk proteins, nitrosourea compounds, vitamin D deficiency, and environmental toxins - though none has been conclusively proven.

Staging of Type 1 DM

Stage	Description
Stage 1	Autoimmunity present (2+ autoantibodies), normoglycemia, presymptomatic
Stage 2	Autoimmunity + dysglycemia, presymptomatic
Stage 3	New-onset clinical hyperglycemia (symptomatic disease)

Presentation

Polyuria, polydipsia, weight loss, fatigue, blurred vision
Often rapid onset; ketoacidosis may be the presenting event
Typically younger patients (children/young adults) but can occur at any age

Management of Type 1 DM

Core principle: Mimic physiologic insulin secretion. Basal insulin is essential to regulate glycogen breakdown, gluconeogenesis, lipolysis, and ketogenesis.

Intensive glycemic management (target HbA1c <7% for most patients):

Multiple Daily Injections (MDI) - basal + prandial insulin
Continuous Subcutaneous Insulin Infusion (CSII/pump)
Sensor-augmented systems - pump + CGM with auto-suspend for low glucose
Automated Insulin Delivery (AID) - pump + CGM + algorithm adjusting basal rate in real time

Insulin preparations used in Type 1 DM:

Preparation	Onset (h)	Peak (h)	Duration (h)
Rapid-acting (aspart, glulisine, lispro)	<0.25	0.5-1.5	3-5
Inhaled human insulin	<0.25	1-2	3
Short-acting (Regular)	0.5-1.0	2-3	4-8
Intermediate (NPH)	2-4	4-10	10-16
Long-acting (glargine, detemir)	2-4	No peak	12-24
Ultra-long-acting (degludec)	1-2	No peak	>24

Emerging therapies:

Teplizumab - humanized anti-CD3 monoclonal antibody approved by FDA to delay onset of stage 3 type 1 DM in patients ≥8 years with stage 2 disease
Stem cell-derived islet transplantation - clinical trials showing promise
Pancreatic islet transplantation - FDA-approved product available; used in severe metabolic instability or when immunosuppression already required

TYPE 2 DIABETES MELLITUS

Pathophysiology

Type 2 DM encompasses a range of disorders with the common phenotype of hyperglycemia, involving:

Insulin resistance (precedes secretory defect)
Impaired insulin secretion (beta-cell dysfunction)
Excessive hepatic glucose production
Abnormal fat metabolism
Systemic low-grade inflammation

Obesity (≥80% of patients, especially visceral/central) drives insulin resistance. The disease is polygenic with >600 genetic loci identified; concordance in identical twins is 70-90%. Risk approaches 70% if both parents are affected.

Ethnic variation is significant:

Latinos: greater insulin resistance
East/South Asians: more beta-cell dysfunction; develop DM at younger age and lower BMI
African Americans: more prone to nonketotic hyperosmolar presentations

Presentation

Often asymptomatic; detected on screening
May present with chronic complications already established
Polyuria, polydipsia, weight loss (less acute than Type 1)
No tendency to ketoacidosis (except under severe stress)

Screening criteria (ADA 2024)

BMI ≥25 kg/m² (or ≥23 kg/m² in Asian Americans) PLUS any risk factor:
- Family history, high-risk race/ethnicity, hypertension, low HDL/high TG, PCOS, acanthosis nigricans, cardiovascular disease, physical inactivity
All adults ≥35 years every 3 years
Prediabetes (IFG, IGT, HbA1c 5.7-6.4%): screen annually

Management of Type 2 DM

Step 1: Medical nutrition therapy (MNT) + exercise (improves insulin sensitivity, promotes weight loss)

Step 2: Pharmacologic therapy - agents are categorized by mechanism:

Glucose-lowering agent classes:

Class	Example	Mechanism	Notes
Biguanides	Metformin	Reduces hepatic glucose production	First-line; reduces FPG + insulin; modest weight loss; max 2000 mg/day; avoid in GFR <30, acidosis, CHF, liver disease
Sulfonylureas	Glimepiride, glipizide, glyburide	ATP-K⁺ channel closure → insulin secretion	Best in early T2DM with residual beta-cell function; risk of hypoglycemia and weight gain
Meglitinides	Repaglinide	Same as sulfonylureas but shorter-acting	Fewer hypoglycemia episodes
GLP-1 receptor agonists	Semaglutide, liraglutide, dulaglutide	Stimulate insulin secretion, suppress glucagon, slow gastric emptying	Weight loss, CV benefit; GI side effects; injectable or oral
DPP-4 inhibitors	Sitagliptin	Prevent GLP-1 degradation	Weight neutral; fewer GI effects
SGLT2 inhibitors	Empagliflozin, dapagliflozin	Promote urinary glucose excretion	CV and renal benefit; risk of DKA (rare), genitourinary infections
Thiazolidinediones	Pioglitazone	PPAR-γ agonist → insulin sensitization	Risk of edema, heart failure, fractures
Alpha-glucosidase inhibitors	Acarbose	Slow carbohydrate absorption	GI side effects; modest efficacy
Insulin	Various	Direct glucose lowering	Used when oral agents inadequate; long-acting ± prandial

Insulin in Type 2 DM: Required when oral agents fail. Large doses may be needed (1-2 units/kg/day) as endogenous production falls. Long-acting insulin (glargine) given at 50% usual dose perioperatively.

Other interventions:

Bariatric/metabolic surgery for BMI >30 kg/m² with inadequately controlled hyperglycemia - 68.2% achieve complete remission within 5 years (though one-third redevelop DM within 5 years)
Very-low-calorie diet (800-1000 kcal/day) under supervision can produce dramatic short-term improvement, especially in recent-onset T2DM

Key Differences: Type 1 vs Type 2

Feature	Type 1 DM	Type 2 DM
Mechanism	Autoimmune beta-cell destruction	Insulin resistance + secretory defect
Insulin deficiency	Absolute	Relative (initially)
Onset	Usually acute; any age, often young	Insidious; typically adults (rising in youth)
Body habitus	Usually lean	Usually overweight/obese (≥80%)
Ketoacidosis risk	High - characteristic	Low (except under severe stress)
Autoantibodies	Present (GAD65, IA-2, ZnT-8, IAA)	Absent
HLA association	DR3/DR4, DQ	Weak
Genetic concordance	~50% (identical twins)	70-90% (identical twins)
Insulin required	Always, immediately	Often eventually; not always initially
Primary treatment	Insulin replacement	Lifestyle + oral agents ± insulin
CVD risk reduction	Important	Paramount (leading cause of death)

Diagnostic Criteria (both types)

Test	Diabetes	Prediabetes
HbA1c	≥6.5%	5.7-6.4%
Fasting plasma glucose (FPG)	≥126 mg/dL (7.0 mmol/L)	100-125 mg/dL (IFG)
2-h OGTT glucose	≥200 mg/dL (11.1 mmol/L)	140-199 mg/dL (IGT)
Random glucose + symptoms	≥200 mg/dL	-

Monitoring Targets

HbA1c goal: <7% for most patients (individualized - stricter in young/motivated; less strict in elderly/hypoglycemia-prone)
Glucose levels: Maintain <180 mg/dL in perioperative/critical care settings
Foot exam: Annually from initial diagnosis
Neuropathy screening: Annually from diagnosis (T2) or after 5 years (T1)
Renal screening: From diagnosis (T2); after 5 years of disease (T1)

- Harrison's Principles of Internal Medicine, 22E (2025), Chapter 415/416, pp. 3227-3292

This is a shared conversation. Sign in to Orris to start your own chat.